Bevacizumab
- PDF / 141,800 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 61 Downloads / 191 Views
1
S
Acute anterior uveitis in elderly patients: 2 case reports Two elderly patients with age-related macular degeneration developed acute anterior uveitis following treatment with intravitreal bevacizumab [dosages not stated]. A 75-year-old woman with a history of hypothyroidism received two doses of bevacizumab, 8 weeks apart. Five days after the second injection, she developed decreased vision, tearing and light sensitivity. Her visual acuity decreased from 20/50 to finger counting, and slit lamp examination showed 1+ conjunctival vascular injection, 1+ corneal oedema and 1+ flare. Following a diagnosis of decompensated corneal dystrophy, she was treated with prednisolone and sodium chloride, and her symptoms resolved within 1 week. Six months later, she began receiving 3-monthly injections of ranibizumab, and her visual acuity improved to 20/40. Bevacizumab was restarted as maintenance therapy, but she developed pain, tearing and light sensitivity 12 days later. Her visual acuity was 20/100, and slit lamp examination revealed 2+ conjunctival vascular injection, corneal oedema and 2+ cell and flare. She was diagnosed with acute anterior uveitis, and treated with homatropine and prednisolone. Her symptoms resolved completely over the following 4 weeks. A 69-year-old man with a history of primary open-angle glaucoma and diabetes mellitus was switched from ranibizumab to bevacizumab, which was administered every 8 weeks. Approximately 2 years later, following a routine bevacizumab injection in the left eye, he developed foreign body sensation and worsening redness. His visual acuity decreased from 20/25 to 20/40, and slit lamp examination showed keratic precipitates with trace cell in the anterior chamber. A diagnosis of acute anterior uveitis was made, and he was treated with prednisolone. Four weeks later, his symptoms had resolved. Antonopoulos C, et al. Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab. Clinical Ophthalmology 5: 1659-1662, No. 1, 23 Nov 2011. Available from: URL: http://dx.doi.org/10.2147/opth.s26880 803069102 USA
0114-9954/10/1397-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 14 Apr 2012 No. 1397
Data Loading...
